for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc

AZN.L

Latest Trade

8,358.72GBp

Change

15.72(+0.19%)

Volume

322,852

Today's Range

8,319.00

 - 

8,400.00

52 Week Range

6,499.80

 - 

10,120.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
8,343.00
Open
8,326.00
Volume
322,852
3M AVG Volume
44.44
Today's High
8,400.00
Today's Low
8,319.00
52 Week High
10,120.00
52 Week Low
6,499.80
Shares Out (MIL)
1,312.77
Market Cap (MIL)
109,543.80
Forward P/E
22.93
Dividend (Yield %)
2.59

Next Event

AstraZeneca PLC at JPMorgan European Healthcare Conference (Virtual)

Latest Developments

更多

EMA Continues To Assess Reports Of Myocarditis, Pericarditis After COVID-19 Vaccination

EMA Advises Against Use Of Vaxzevria In People With History Of Capillary Leak Syndrome

Astrazeneca Appoints Aradhana Sarin As New CFO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Industry

Biotechnology & Drugs

Contact Info

1 Francis Crick Avenue

CB2 0AA

United Kingdom

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Marc Dunoyer

Chief Financial Officer, Executive Director

Jeffrey A. Pott

Chief Human Resource Officer, General Counsel

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Key Stats

1.86 mean rating - 28 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

22.1K

2019

24.4K

2020

26.6K

2021(E)

32.0K
EPS (USD)

2018

3.460

2019

3.500

2020

4.020

2021(E)

5.100
Price To Earnings (TTM)
38.95
Price To Sales (TTM)
5.60
Price To Book (MRQ)
10.71
Price To Cash Flow (TTM)
22.32
Total Debt To Equity (MRQ)
139.51
LT Debt To Equity (MRQ)
123.87
Return on Investment (TTM)
9.63
Return on Equity (TTM)
6.48

Latest News

Latest News

UPDATE 4-AstraZeneca antibody cocktail fails to prevent COVID-19 in large trial

* No reliable results from trial to show prevention of infections

FACTBOX-Vaccines delivered under COVAX sharing scheme for poorer countries

The COVAX facility, backed by the World Health Organization (WHO) and the Global Alliance for Vaccines and Immunization (GAVI), aims to secure 2 billion vaccine doses for lower-income countries by the end of 2021. The following tables list countries that have received vaccines...

UPDATE 2-AstraZeneca shots have good risk-benefit profile for over 60s, says EMA official

The head of the EU drug regulator's COVID-19 task force said on Sunday that AstraZeneca's coronavirus vaccine had a favourable risk-benefit profile for all age groups and particularly for those aged over 60.

UPDATE 3-EU adds another rare blood condition as side effect of AstraZeneca shot

Europe's drug regulator on Friday identified another very rare blood condition as a potential side effect of AstraZeneca's COVID-19 vaccine and said it was looking into cases of heart inflammation after inoculation with all coronavirus shots.

UPDATE 1-Taiwan says Thailand prioritising AstraZeneca shots for itself

Thailand is prioritising for itself AstraZeneca Plc's COVID-19 vaccines produced in the southeast Asian nation because of the severity of the pandemic there, thus delaying deliveries to Taiwan, President Tsai Ing-wen said on Friday.

UPDATE 3-Two Australian states on COVID-19 alert after infected woman's interstate travel

* Second AstraZeneca blood-clot death reported (Adds vaccine-related death, cruise ship ban extension)

COVID SCIENCE-Meat-free diet may lower severe disease risk; no serious problems found with AstraZeneca shot in Scotland

The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

UPDATE 1-EMA highlights guidance not to use heparin for COVID-19 vaccine-linked clots

The European Medicines Agency (EMA) on Monday pushed guidance for doctors not to use the blood thinner heparin to treat rare blood clots and low blood platelets in people who got AstraZeneca's or Johnson & Johnson's COVID-19 shots.

EMA highlights guidance not to use heparin for COVID-19 vaccine-linked clots

The European Medicines Agency (EMA) on Monday highlighted guidance for doctors which calls for them to avoid heparin when treating rare blood clots and low platelet counts in patients who received AstraZeneca's or Johnson & Johnson's COVID-19 vaccines.

UPDATE 1-NetScientific's unit signs deal to sell AstraZeneca's COVID-19 test

British life sciences company NetScientific Plc said on Monday that one of its subsidiaries has entered an exclusive licensing agreement with AstraZeneca Plc to globally sell a COVID-19 test.

NetScientific's unit signs deal to sell AstraZeneca's COVID-19 test

British life sciences company NetScientific Plc said on Monday one of its subsidiaries has entered an exclusive licensing agreement with AstraZeneca Plc to globally sell a COVID-19 test.

REFILE-UPDATE 1-AstraZeneca's Lynparza reduces relapse, death in breast cancer patients

AstraZeneca Plc's drug Lynparza reduced the risk of relapse and death in breast cancer patients with certain mutations in a late-stage trial, the British drugmaker said on Thursday.

UPDATE 3-AstraZeneca moves finance chief to new role after Alexion deal

* Current Alexion chief executive's future unclear (Adds detail, context, executive comment)

UPDATE 6-Taiwan's COVID-19 vaccine stocks more than doubled by Japan donation

Japan delivered to Taiwan 1.24 million doses of AstraZeneca PLC's coronavirus vaccine on Friday for free, in a gesture that will more than double the amount of shots the island has received to date.

AstraZeneca's Lynparza reduces relapse and death in breast cancer patients

AstraZeneca Plc's drug Lynparza reduced the risk of relapse and death in patients with breast cancer in a late stage trial, the British drugmaker said on Thursday. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)

UPDATE 1-AstraZeneca in talks to shift COVID-19 vaccine production to Catalent factory - NYT

AstraZeneca Plc is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Baltimore plant to a factory owned by Catalent Inc, the New York Times reported, citing people familiar with the matter.

AstraZeneca in talks to shift COVID-19 vaccine production to Catalent factory - NYT

AstraZeneca Plc is in talks with the U.S. government to shift production of its COVID-19 vaccine from a Baltimore plant to a factory owned by Catalent Inc , the New York Times reported on Wednesday, citing people familiar with the matter.

UPDATE 3-Canada panel says COVID-19 shots can be mixed, cases fall steadily

An official Canadian panel on Tuesday said people who received a first shot of AstraZeneca PLC's COVID-19 vaccine can choose to receive a different shot for their second dose, dealing another potential blow to the pharmaceutical giant.

Canada panel says COVID-19 vaccines can be mixed, move could hit AstraZeneca

An official Canadian panel on Tuesday said people who received a first shot of AstraZeneca PLC's COVID-19 vaccine can choose to receive a different shot for their second dose, dealing another potential blow to the pharmaceutical giant.

UPDATE 2-Russia pauses approval of combined AstraZeneca/Sputnik V vaccine trial, requests data

The Russian health ministry's ethical committee has declined to approve clinical trials in Russia combining a British shot from AstraZeneca and Oxford University with Russia's Sputnik V vaccine, an AstraZeneca official told Reuters on Friday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up